Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
3.82 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 164.07 | 1.189 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 123.995 | 10.755 | 21.135 | 13.98 | 8.712 | 8.123 | 0.956 | 0.952 | 0.978 | 0.999 | 9.336 | 4.655 | 6.477 | 19.303 | 0 | 0 | 0 |
| Gross Profit
| 40.075 | -9.566 | -21.135 | -13.98 | -8.712 | -8.123 | -0.956 | -0.952 | -0.978 | -0.999 | -9.336 | -4.655 | -6.477 | -19.303 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.244 | -8.045 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 282.336 | 344.077 | 294.781 | 259.039 | 201.727 | 166.023 | 99.828 | 71.615 | 28.037 | 15.47 | 2.705 | 1.329 | 1.656 | 1.756 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 27.699 | 104.097 | 83.664 | 60.21 | 40.849 | 28.43 | 21.262 | 25.602 | 12.39 | 9.336 | 4.655 | 6.477 | 0 | 0 | 0.014 | 0 |
| Selling & Marketing Expenses
| 0 | 79.217 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 153.017 | 106.916 | 104.097 | 83.664 | 60.21 | 40.849 | 28.43 | 21.262 | 25.602 | 12.39 | 9.336 | 4.655 | 6.477 | 19.303 | 0 | 0.014 | 0.026 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.656 | 0 | 19.303 | 0.815 | 0.016 | 0.057 |
| Operating Expenses
| 435.353 | 450.993 | 398.878 | 342.703 | 261.937 | 206.872 | 128.258 | 92.877 | 53.639 | 27.86 | 12.04 | 22.641 | 8.133 | 21.058 | 0.815 | 0.016 | 0.057 |
| Operating Income
| -395.278 | -460.559 | -398.878 | -342.703 | -261.937 | -206.872 | -128.258 | -92.877 | -53.639 | -27.86 | -12.04 | -22.641 | -8.133 | -21.218 | -0.815 | -0.016 | -0.057 |
| Operating Income Ratio
| -2.409 | -387.35 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 20.273 | 13.043 | 2.985 | 0.451 | 2.356 | 9.316 | 4.678 | 0.813 | 0.745 | 0.2 | 0.006 | -2.741 | 4.825 | -4.476 | -0.793 | 0 | 0 |
| Income Before Tax
| -375.005 | -447.516 | -395.893 | -342.252 | -259.581 | -197.556 | -123.58 | -92.064 | -52.894 | -27.66 | -12.035 | -25.381 | -3.308 | -25.694 | -1.608 | -0.016 | -0.057 |
| Income Before Tax Ratio
| -2.286 | -376.38 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -2.828 | -3.479 | -5.97 | -14.431 | -2.356 | -10.485 | 4.678 | -0.952 | -0.978 | -0.999 | 0 | 0.445 | 2.42 | 4.636 | 0.793 | 0 | 0 |
| Net Income
| -372.177 | -444.037 | -389.923 | -327.821 | -257.225 | -187.071 | -123.58 | -92.064 | -52.894 | -27.66 | -12.035 | -25.381 | -3.308 | -25.694 | -1.608 | -0.016 | -0.057 |
| Net Income Ratio
| -2.268 | -373.454 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.28 | -1.89 | -2.45 | -2.14 | -1.86 | -1.5 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 | -2.6 | -4.14 | -33.84 | -2.46 | -0.041 | -0.047 |
| EPS Diluted
| -1.28 | -1.89 | -2.45 | -2.14 | -1.86 | -1.5 | -1.27 | -1.41 | -0.96 | -0.62 | -0.48 | -2.6 | -4.14 | -33.84 | -2.46 | -0.041 | -0.047 |
| EBITDA
| -395.278 | -427.432 | -374.758 | -328.272 | -250.869 | -189.433 | -122.624 | -91.112 | -51.916 | -26.661 | -11.946 | -24.93 | 0.509 | -20.54 | -1.549 | -0.014 | -0.056 |
| EBITDA Ratio
| -2.409 | -359.489 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |